| Literature DB >> 32449053 |
C Darreau1, F Martino2, M Saint-Martin1, S Jacquier3, J F Hamel4, M A Nay5, N Terzi6, G Ledoux7, F Roche-Campo8, L Camous9, F Pene10, T Balzer11, F Bagate12, J Lorber13, P Bouju14, C Marois15, R Robert16, S Gaudry17, M Commereuc18, M Debarre19, N Chudeau1, P Labroca20, K Merouani21, P Y Egreteau22, V Peigne23, C Bornstain24, E Lebas25, F Benezit26, S Vally27, S Lasocki28, A Robert29, A Delbove30, N Lerolle31.
Abstract
BACKGROUND: No recommendation exists about the timing and setting for tracheal intubation and mechanical ventilation in septic shock. PATIENTS AND METHODS: This prospective multicenter observational study was conducted in 30 ICUs in France and Spain. All consecutive patients presenting with septic shock were eligible. The use of tracheal intubation was described across the participating ICUs. A multivariate analysis was performed to identify parameters associated with early intubation (before H8 following vasopressor onset).Entities:
Keywords: Mechanical ventilation; Septic shock; Tracheal intubation
Year: 2020 PMID: 32449053 PMCID: PMC7245631 DOI: 10.1186/s13613-020-00668-6
Source DB: PubMed Journal: Ann Intensive Care ISSN: 2110-5820 Impact factor: 6.925
Fig. 1Hazard of being intubated from H0 to H72
Fig. 2Percentage of patients intubated at H8 and H72 in the 18 centers with at last 20 patients included
Patient’s demographic data and outcome according intubation during the ICU stay
| Patients intubated early H0–H8 ( | Patients intubated late H8–H72 (n = 114) | Patients never intubated ( | ||
|---|---|---|---|---|
| Age, years | 66.5 ± 13.9 | 64.6 ± 13.5 | 64.9 ± 14.6 | 0.30 |
| Sex, female | 82 (39.4%) | 35 (30.7%) | 196 (36.6%) | 0.30 |
| Weight, kg | 77.1 ± 18.7 | 76.7 ± 18.8 | 75.9 ± 19.9 | 0.32 |
| Chronic heart failure, NYHA > 2 | 15 (7.2%) | 11 (9.7%) | 55 (10.3%) | 0.43 |
| Chronic respiratory failure | 33 (15.8%) | 16 (14.2%) | 84 (15.7%) | 0.93 |
| Home oxygen therapy | 4 (1.9%) | 3 (2.6%) | 6 (1.1%) | 0.33 |
| Home non-invasive or invasive ventilation therapy | 2 (1%) | 4 (3.5%) | 7 (1.3%) | 0.18 |
| Chronic renal failure | 32 (15.3%) | 15 (13.2%) | 88 (16.5%) | 0.72 |
| Dialysis | 10 (4.8%) | 2 (1.8%) | 29 (5.4%) | 0.28 |
| Cirrhosis | 24 (11.5%) | 6 (5.3%) | 36 (6.7%) | 0.07 |
| Immunosuppression | 51 (24.4%) | 40 (35.4%) | 161 (30.3%) | 0.12 |
| Chemotherapy | 26 (12.4%) | 30 (36.3%) | 80 (14.9%) | 0.02 |
| Corticosteroid therapy > 20 mg/j | 12 (5.7%) | 10 (8.8%) | 41 (7.6%) | 0.98 |
| Organ transplant or bone marrow transplant | 11 (5.3%) | 5 (4.4%) | 36 (6.7%) | 0.37 |
| Human immunodeficiency virus | 6 (2.7%) | 0 (0.00%) | 13 (2.4%) | 0.07 |
| Other immunosuppressive therapy | 11 (5.3%) | 8 (7%) | 46 (8.6%) | 0.44 |
| Neutropenia < 500/mm3 | 18 (13.4%) | 13 (11.4%) | 37 (6.8%) | 0.13 |
| Infection site | ||||
| Heart | 5 (2.4%) | 5 (4.6%) | 10 (2%) | 0.27 |
| Skin | 26 (12.4%) | 12 (11%) | 55 (10.8%) | 0.69 |
| Digestive | 62 (29.7%) | 48 (43.2%) | 136 (26.8%) | 0.01 |
| Gynecological | 3 (1.4%) | 0 (0.00%) | 1 (0.2%) | 0.09 |
| Material | 10 (7.8%) | 7 (6.5%) | 32 (6.4%) | 0.83 |
| Neurological | 0 (0.00%) | 1 (0.9%) | 1 (0.2%) | 0.31 |
| Upper respiratory tract | 4 (1.9%) | 2 (1.9%) | 7 (1.4%) | 0.65 |
| Bone | 2 (1%) | 1 (0.9%) | 5 (1%) | 0.99 |
| Lung | 59 (28.2%) | 29 (26.9%) | 124 (24.2%) | 0.37 |
| Blood | 55 (27.6%) | 35 (31.8%) | 129 (25.5%) | 0.37 |
| Urinary | 37 (18.6%) | 9 (8.3%) | 144 (28.1%) | < 0.001 |
| Others | 8 (4%) | 2 (1.9%) | 14 (2.8%) | 0.73 |
| Pathogens | ||||
| Gram-positive cocci | 61 (31.1%) | 35 (32.4%) | 122 (24%) | 0.06 |
| Gram-negative bacilli | 104 (49.8%) | 53 (48.6%) | 243 (47.3%) | 0.52 |
| Fungus, parasite | 9 (4.6%) | 3 (2.8%) | 6 (1.2%) | 0.02 |
| Others | 9 (4.6%) | 5 (4.7%) | 20 (4%) | 0.84 |
| Non-identified | 46 (23.6%) | 29 (26.9%) | 162 (31.6%) | 0.1 |
| Infection type | ||||
| Nosocomial infection | 147 (71%) | 64 (56.6%) | 329 (61.6%) | 0.08 |
| Community-acquired infection | 20 (9.7%) | 17 (15%) | 75 (14%) | |
| Healthcare associated infection | 40 (19.3%) | 32 (28.3%) | 130 (24.3%) | |
| Acute physiological parameters and treatment | ||||
| pHa | 7.26 ± 0.15 | 7.33 ± 0.1 | 7.38 ± 0.1 | < 0.001 |
| PaO2, mmHga | 103.8 ± 54.2 | 87.9 ± 29.0 | 93.8 ± 30.1 | 0.16 |
| PaCO2, mmHga | 36.5 ± 14.5 | 32.2 ± 8.8 | 32.3 ± 8.8 | 0.02 |
| SpO2, %a | 93.6 ± 5.9 | 92.3 ± 6.4 | 95.2 ± 3.3 | 0.03 |
| Lactatesa | 5.4 ± 4.0 | 3.5 ± 2.3 | 2.9 ± 2.3 | < 0.001 |
| Respiratory ratea | 28.9 ± 7.9 | 28.6 ± 6.6 | 25.7 ± 6.7 | < 0.001 |
| Inability to clear tracheal secretionsa | 48 (23.7%) | 13 (11.6%) | 40 (7.6%) | < 0.001 |
| Use of accessory respiratory musclea | 101 (49.8%) | 22 (19.8%) | 52 (9.9%) | < 0.001 |
| Standard nasal oxygenb | 70 (35.7%) | 53 (49.1%) | 273 (52.8%) | < 0.001 |
| High concentration mask oxygenb | 76 (39.2%) | 17 (15.6%) | 55 (10.9%) | < 0.001 |
| High-flow nasal therapyb | 22 (11.4%) | 21 (19.6%) | 41 (8.1%) | < 0.01 |
| Non-invasive ventilation therapyb | 20 (10.4%) | 8 (7.6%) | 26 (5.2%) | 0.04 |
| PaO2/FiO2 ratioa | 182 (88–295) | 192 (127–313) | 295 (208–395) | < 0.001 |
| Glasgow coma scorea | 12.4 ± 3.9 | 14.5 ± 1.5 | 14.7 ± 0.9 | < 0.001 |
| Vasopressor dosea, µg/kg/min | 0.74 ± 0.66 | 0.50 ± 0.46 | 0.35 ± 0.37 | < 0.001 |
| Cumulative fluid from first hypotension to H0 | 2218.8 ± 1243.2 | 1958.6 ± 1137.5 | 2179.8 ± 1327.1 | 0.25 |
| SAPS II score at 24 h | 67.9 ± 22.0 | 58.8 ± 18.8 | 46.9 ± 13.8 | < 0.001 |
Data are n (%) or mean ± SD
aWorst value recorded between H0 and H8, or between H0 and immediately before intubation if intubation performed before H8
bAt H0
Fig. 3Intubation frequency at H8 and H72 in patients with and without neurological or respiratory standard criteria for theoretical immediate intubation by H8
Multivariate analysis for explaining early intubation
| Odds ratio [95% confidence interval] | % of | Covariate rank in | ||
|---|---|---|---|---|
| Use of accessory respiratory musclesa | 5.63 [2.83–11.82] | < 0.001 | 12.8 | 3 |
| pH (for each 0.1 decrease)a | 1.51 [1.09–2.97] | 0.02 | 3.8 | 7 |
| Glasgow score (reference ≥ 14)a | 39.5 | 1 | ||
| 10–13 vs ≥ 14 | 3.03 [1.20–7.63] | 0.01 | ||
| <10 vs ≥ 14 | 39.95 [10.13–134.85] | < 0.001 | ||
| Inability to clear tracheal secretionsa | 2.64 [1.38–3.96] | 0.02 | 6.02 | 6 |
| Vasopressor (for each 1 μg/kg/min increase)a | 2.34 [1.38–3.96] | 0.001 | 5.7 | 5 |
| Lactate (for each 1 mmol/L increase)a | 1.11 [1.01–1.21] | 0.02 | 8.6 | 4 |
Overall r2 of the model was 0.6
Parameters entered in the model not presented in the table, with a P-value > 0.1: age, sex, weight, NYHA status, chronic respiratory failure, chronic renal failure, immunosuppression, pulmonary and urinary site of infection, pathogen, respiratory rate, PaCO2, PaO2/FiO2 ratio, fluid loading from first hypotension to H0
aWorst value recorded between H0 and H8, or between H0 and immediately before intubation if performed before H8
Patient’s outcome according to intubation during the ICU stay
| Patients intubated early H0–H8 ( | Patients intubated late H8–H72 ( | Patients never intubated ( | Overall | Intubated early vs. late | |
|---|---|---|---|---|---|
| Number of days alive without vasopressor at day 28 | 13.7 ± 14.3 | 13.7 ± 11.4 | 24.3 ± 17.5 | < 0.001 | 0.99 |
| Number of days alive without dialysis at day 28 | 15.8 ± 14.7 | 17.4 ± 11.5 | 26.2 ± 17.4 | <0.001 | 0.09 |
| Number of days alive without invasive ventilation at day 28 | 11.5 ± 14.1 | 11.9 ± 10.5 | 26.3 ± 17.5 | < 0.001 | 0.145 |
| Length of ICU stay, days | 14.7 ± 35.2 | 15.2 ± 20.4 | 5.1 ± 37.1 | < 0.001 | 0.01 |
| Length of hospital stay, days | 22.7 ± 34.0 | 29.3 ± 41.0 | 21.7 ± 50.9 | 0.01 | 0.01 |
| ICU mortality | 97 (46.9%) | 44 (38.6%) | 32 (6%) | < 0.001 | 0.2 |
| Hospital mortality | 106 (51%) | 56 (49.1%) | 75 (14.1%) | < 0.001 | 0.8 |
| 28th-day mortality | 97 (46.9%) | 47 (41.2%) | 70 (13.1%) | < 0.001 | 0.4 |
Fig. 428-day survival according to intubation status. P = 0.87 for comparison between patients intubated early vs. delayed, and P = 0.001 for comparisons between patients intubated early vs. never intubated